{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:08:54Z","timestamp":1782860934959,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40291-026-00858-1","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:55:04Z","timestamp":1780314904000},"page":"561-573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Cytotoxic T-Cell Effector Function with Granzyme B PET: Translational Advances Toward Predicting Immunotherapy Outcomes"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-5496","authenticated-orcid":false,"given":"Luca","family":"Filippi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elife","family":"Akg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"858_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.14216\/kjco.24009","volume":"20","author":"S Ahuja","year":"2024","unstructured":"Ahuja S, Zaheer S. The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives. Korean J Clin Oncol. 2024;20:51\u201373. https:\/\/doi.org\/10.14216\/kjco.24009.","journal-title":"Korean J Clin Oncol"},{"key":"858_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/pme-2023-0054","volume":"21","author":"E Faghfuri","year":"2024","unstructured":"Faghfuri E. Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells\u00a0and vaccines. Per Med. 2024;21:45\u201357. https:\/\/doi.org\/10.2217\/pme-2023-0054.","journal-title":"Per Med"},{"key":"858_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40336-023-00614-z","volume":"12","author":"ML De Rimini","year":"2024","unstructured":"De Rimini ML, Bianchi A, Annovazzi A, D\u2019Arienzo D, Valente T, Sciuto R, et al. Lymphoid organs\u2019 metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy: an exploratory study. Clin Transl Imaging. 2024;12:213\u201323. https:\/\/doi.org\/10.1007\/s40336-023-00614-z.","journal-title":"Clin Transl Imaging"},{"key":"858_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1148\/radiol.2018181349","volume":"290","author":"M Nishino","year":"2019","unstructured":"Nishino M, Hatabu H, Hodi FS. Imaging of cancer immunotherapy: Current approaches and future directions. Radiology. 2019;290:9\u201322. https:\/\/doi.org\/10.1148\/radiol.2018181349.","journal-title":"Radiology"},{"key":"858_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1392535","volume":"15","author":"R Thompson","year":"2024","unstructured":"Thompson R, Cao X. Reassessing Granzyme B: unveiling perforin-independent versatility in immune responses and therapeutic potentials. Front Immunol. 2024;15:1392535. https:\/\/doi.org\/10.3389\/fimmu.2024.1392535.","journal-title":"Front Immunol"},{"key":"858_CR6","first-page":"259","volume":"2","author":"Z Fan","year":"2005","unstructured":"Fan Z, Zhang Q. Molecular mechanisms of lymphocyte-mediated cytotoxicity. Cell Mol Immunol. 2005;2:259\u201364.","journal-title":"Cell Mol Immunol"},{"key":"858_CR7","doi-asserted-by":"publisher","first-page":"17907","DOI":"10.1074\/jbc.272.29.17907","volume":"272","author":"NA Thornberry","year":"1997","unstructured":"Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, et al. A combinatorial approach defines specificities of members of the Caspase family and Granzyme B. J Biol Chem. 1997;272:17907\u201311. https:\/\/doi.org\/10.1074\/jbc.272.29.17907.","journal-title":"J Biol Chem"},{"key":"858_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061436","volume":"14","author":"E Tibbs","year":"2022","unstructured":"Tibbs E, Cao X. Emerging canonical and non-canonical roles of Granzyme B in health and disease. Cancers (Basel). 2022;14:1436. https:\/\/doi.org\/10.3390\/cancers14061436.","journal-title":"Cancers (Basel)"},{"key":"858_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.trecan.2017.04.001","volume":"3","author":"M Arias","year":"2017","unstructured":"Arias M, Mart\u00ednez-Lostao L, Santiago L, Ferrandez A, Granville DJ, Pardo J. The untold story of granzymes in oncoimmunology: Novel opportunities with old acquaintances. Trends Cancer. 2017;3:407\u201322. https:\/\/doi.org\/10.1016\/j.trecan.2017.04.001.","journal-title":"Trends Cancer"},{"key":"858_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/cdd.2009.206","volume":"17","author":"SP Cullen","year":"2010","unstructured":"Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010;17:616\u201323. https:\/\/doi.org\/10.1038\/cdd.2009.206.","journal-title":"Cell Death Differ"},{"key":"858_CR11","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/0008-5472.CAN-16-3346","volume":"77","author":"BM Larimer","year":"2017","unstructured":"Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 2017;77:2318\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3346.","journal-title":"Cancer Res"},{"key":"858_CR12","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1097\/RLU.0000000000006098","volume":"50","author":"J Zhou","year":"2025","unstructured":"Zhou J, Zhou M, Chen W, Liu Y, Hai W, Huang J, et al. 68Ga-NODAGA-SNA006 PET\/CT imaging of tumor CD8+ T-cell infiltration predicts immunotherapy response in lung cancer. Clin Nucl Med. 2025;50:1152\u201360. https:\/\/doi.org\/10.1097\/RLU.0000000000006098.","journal-title":"Clin Nucl Med"},{"key":"858_CR13","doi-asserted-by":"publisher","first-page":"1428541","DOI":"10.3389\/fimmu.2024.1428541","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang J, Du B, Wang Y, Cui Y, Wang S, Zhao Y, et al. The role of CD8 PET imaging in guiding cancer immunotherapy. Front Immunol. 2024;15:1428541. https:\/\/doi.org\/10.3389\/fimmu.2024.1428541.","journal-title":"Front Immunol"},{"key":"858_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013837","volume":"14","author":"Y Chen","year":"2026","unstructured":"Chen Y, Liu X, Hu Y, Li A, Zeng B, Wang P, et al. PD-L1-targeted PET imaging for non-invasive assessment of immunotherapy response in lung cancer. J Immunother Cancer. 2026;14:e013837. https:\/\/doi.org\/10.1136\/jitc-2025-013837.","journal-title":"J Immunother Cancer"},{"key":"858_CR15","doi-asserted-by":"publisher","first-page":"13021","DOI":"10.1021\/jacs.5c21595","volume":"148","author":"C Liu","year":"2026","unstructured":"Liu C, Zhang S, Chen J, Geng H, Li H, Zhang Z, et al. Directional engineering of cyclic \u03b2-hairpin peptides for PET\/CT imaging of PD-L1. J Am Chem Soc. 2026;148:13021\u201334. https:\/\/doi.org\/10.1021\/jacs.5c21595.","journal-title":"J Am Chem Soc"},{"key":"858_CR16","doi-asserted-by":"publisher","unstructured":"H\u00f6bart J, Da Pieve C, Raes F, Borys D, M\u0105czy\u0144ska J, Sharma G, et al. PD-L1 immuno-PET reveals systemic effects of localized oncolytic virotherapy in a mouse model of head and neck cancer. J Nucl Med. 2026. https:\/\/doi.org\/10.2967\/jnumed.125.270922.","DOI":"10.2967\/jnumed.125.270922"},{"key":"858_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.62347\/KSFZ9854","volume":"15","author":"JS Patel","year":"2025","unstructured":"Patel JS. Visualizing T-cell activation: PET imaging of CXCL9 as a window into the tumor immune response. Am J Nucl Med Mol Imaging. 2025;15:212\u20134. https:\/\/doi.org\/10.62347\/KSFZ9854.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"858_CR18","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/cancers12061615","volume":"12","author":"TE K\u00e4hk\u00f6nen","year":"2020","unstructured":"K\u00e4hk\u00f6nen TE, Halleen JM, Bernoulli J. Immunotherapies and metastatic cancers: understanding utility and predictivity of human immune cell engrafted mice in preclinical drug development. Cancers. 2020;12:1615. https:\/\/doi.org\/10.3390\/cancers12061615.","journal-title":"Cancers"},{"key":"858_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.745","volume":"5","author":"V Janitri","year":"2024","unstructured":"Janitri V, ArulJothi KN, Ravi Mythili VM, Singh SK, Prasher P, Gupta G, et al. The roles of patient-derived xenograft models and artificial intelligence toward precision medicine. MedComm. 2024;5:e745. https:\/\/doi.org\/10.1002\/mco2.745.","journal-title":"MedComm."},{"key":"858_CR20","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-18-2407","volume":"25","author":"BM Larimer","year":"2019","unstructured":"Larimer BM, Bloch E, Nesti S, Austin EE, Wehrenberg-Klee E, Boland G, et al. The effectiveness of checkpoint inhibitor combinations and administration timing can be measured by granzyme B PET imaging. Clin Cancer Res. 2019;25:1196\u2013205. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2407.","journal-title":"Clin Cancer Res"},{"key":"858_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000291","volume":"8","author":"T LaSalle","year":"2020","unstructured":"LaSalle T, Austin EE, Rigney G, Wehrenberg-Klee E, Nesti S, Larimer B, et al. Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response. J Immunother Cancer. 2020;8:e000291. https:\/\/doi.org\/10.1136\/jitc-2019-000291.","journal-title":"J Immunother Cancer"},{"key":"858_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.ijrobp.2023.12.047","volume":"118","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Deshane JS, Yang ES, Larimer B. A novel translational PET imaging approach to quantifying distal tumor immune activation after targeted radiation therapy and checkpoint blockade. Int J Radiat Oncol Biol Phys. 2024;118:1217\u201327. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.12.047.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"858_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12967-025-07419-w","volume":"24","author":"X Tong","year":"2025","unstructured":"Tong X, Jiang Y, Bi N. The application and prospect of granzyme B-targeted PET imaging in cancer immunotherapy. J Transl Med. 2025;24:59. https:\/\/doi.org\/10.1186\/s12967-025-07419-w.","journal-title":"J Transl Med"},{"key":"858_CR24","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1021\/acscentsci.1c00529","volume":"7","author":"N Zhao","year":"2021","unstructured":"Zhao N, Bardine C, Louren\u00e7o AL, Wang Y, Huang Y, Cleary SJ, et al. In vivo measurement of granzyme proteolysis from activated immune cells with PET. ACS Cent Sci. 2021;7:1638\u201349. https:\/\/doi.org\/10.1021\/acscentsci.1c00529.","journal-title":"ACS Cent Sci"},{"key":"858_CR25","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s11307-020-01519-3","volume":"22","author":"JL Goggi","year":"2020","unstructured":"Goggi JL, Tan YX, Hartimath SV, Jieu B, Hwang YY, Jiang L, et al. Granzyme B PET imaging of immune checkpoint inhibitor combinations in colon cancer phenotypes. Mol Imaging Biol. 2020;22:1392\u2013402. https:\/\/doi.org\/10.1007\/s11307-020-01519-3.","journal-title":"Mol Imaging Biol"},{"key":"858_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9305277","volume":"2021","author":"JL Goggi","year":"2021","unstructured":"Goggi JL, Ramasamy B, Tan YX, Hartimath SV, Tang JR, Cheng P, et al. Granzyme B PET imaging stratifies immune checkpoint inhibitor response in hepatocellular carcinoma. Mol Imaging. 2021;2021:9305277. https:\/\/doi.org\/10.1155\/2021\/9305277.","journal-title":"Mol Imaging"},{"key":"858_CR27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s11307-020-01477-w","volume":"22","author":"JL Goggi","year":"2020","unstructured":"Goggi JL, Hartimath SV, Hwang Y, Tan YX, Khanapur S, Ramasamy B, et al. Examining immunotherapy response using multiple radiotracers. Mol Imaging Biol. 2020;22:993\u20131002. https:\/\/doi.org\/10.1007\/s11307-020-01477-w.","journal-title":"Mol Imaging Biol"},{"key":"858_CR28","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2214\/AJR.21.26538","volume":"218","author":"S Sheikhbahaei","year":"2022","unstructured":"Sheikhbahaei S, Marcus CV, Sadaghiani MS, Rowe SP, Pomper MG, Solnes LB. Imaging of cancer immunotherapy: response assessment methods, atypical response patterns, and immune-related adverse events, from the AJR special series on imaging of inflammation. AJR Am J Roentgenol. 2022;218:940\u201352. https:\/\/doi.org\/10.2214\/AJR.21.26538.","journal-title":"AJR Am J Roentgenol"},{"key":"858_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00259-022-05986-4","volume":"50","author":"C Jiang","year":"2023","unstructured":"Jiang C, Tian Q, Xu X, Li P, He S, Chen J, et al. Enhanced antitumor immune responses via a new agent [131I]-labeled dual-target immunosuppressant. Eur J Nucl Med Mol Imaging. 2023;50:275\u201386. https:\/\/doi.org\/10.1007\/s00259-022-05986-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"858_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-021-00141-0","volume":"6","author":"SJ Archibald","year":"2021","unstructured":"Archibald SJ, Allott L. The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules. EJNMMI Radiopharm Chem. 2021;6:30. https:\/\/doi.org\/10.1186\/s41181-021-00141-0.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"858_CR31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s11307-021-01596-y","volume":"23","author":"JL Goggi","year":"2021","unstructured":"Goggi JL, Hartimath SV, Xuan TY, Khanapur S, Jieu B, Chin HX, et al. Granzyme B PET imaging of combined chemotherapy and immune checkpoint inhibitor therapy in colon cancer. Mol Imaging Biol. 2021;23:714\u201323. https:\/\/doi.org\/10.1007\/s11307-021-01596-y.","journal-title":"Mol Imaging Biol"},{"key":"858_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010150","volume":"14","author":"SV Hartimath","year":"2022","unstructured":"Hartimath SV, Ramasamy B, Xuan TY, Rong TJ, Khanapur S, Cheng P, et al. Granzyme B PET imaging in response to in situ vaccine therapy combined with \u03b1PD1 in a murine colon cancer model. Pharmaceutics. 2022;14:150. https:\/\/doi.org\/10.3390\/pharmaceutics14010150.","journal-title":"Pharmaceutics"},{"key":"858_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071460","volume":"14","author":"C De Aguiar Ferreira","year":"2022","unstructured":"De Aguiar Ferreira C, Heidari P, Ataeinia B, Sinevici N, Granito A, Kumar HM, et al. Immune checkpoint inhibitor-mediated cancer theranostics with radiolabeled anti-Granzyme B peptide. Pharmaceutics. 2022;14:1460. https:\/\/doi.org\/10.3390\/pharmaceutics14071460.","journal-title":"Pharmaceutics"},{"key":"858_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161065","volume":"132","author":"H Zhou","year":"2022","unstructured":"Zhou H, Wang Y, Xu H, Shen X, Zhang T, Zhou X, et al. Noninvasive interrogation of CD8+ t cell effector function for monitoring early tumor responses to immunotherapy. J Clin Invest. 2022;132:e161065. https:\/\/doi.org\/10.1172\/JCI161065.","journal-title":"J Clin Invest"},{"key":"858_CR35","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2967\/jnumed.124.267529","volume":"65","author":"Q Liu","year":"2024","unstructured":"Liu Q, Xu X, Yang Z, Zhang J, Li J, Qiao Y, et al. Granzyme B PET\/CT imaging evaluates early response to immunotherapy in gastric cancer. J Nucl Med. 2024;65:1695\u2013701. https:\/\/doi.org\/10.2967\/jnumed.124.267529.","journal-title":"J Nucl Med"},{"key":"858_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53197-2","volume":"15","author":"X Shen","year":"2024","unstructured":"Shen X, Zhou H, Zhou X, Liu Z, Meng X, Zhang L, et al. 68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial. Nat Commun. 2024;15:8791. https:\/\/doi.org\/10.1038\/s41467-024-53197-2.","journal-title":"Nat Commun"},{"key":"858_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2024.1331364","volume":"4","author":"AG Shea","year":"2024","unstructured":"Shea AG, Idrissou MB, Torres AI, Chen T, Hernandez R, Morris ZS, et al. Immunological effects of radiopharmaceutical therapy. Front Nucl Med. 2024;4:1331364. https:\/\/doi.org\/10.3389\/fnume.2024.1331364.","journal-title":"Front Nucl Med"},{"key":"858_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.semradonc.2023.03.011","volume":"33","author":"B Bednarz","year":"2023","unstructured":"Bednarz B. Theranostics and patient-specific dosimetry. Semin Radiat Oncol. 2023;33:317\u201326. https:\/\/doi.org\/10.1016\/j.semradonc.2023.03.011.","journal-title":"Semin Radiat Oncol"},{"key":"858_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01844-3","volume":"26","author":"Y Lu","year":"2024","unstructured":"Lu Y, Houson HA, Gallegos CA, Mascioni A, Jia F, Aivazian A, et al. Evaluating the immunologically \u201ccold\u201d tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models. Breast Cancer Res. 2024;26:104. https:\/\/doi.org\/10.1186\/s13058-024-01844-3.","journal-title":"Breast Cancer Res"},{"key":"858_CR40","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s12149-023-01852-x","volume":"37","author":"L Evangelista","year":"2023","unstructured":"Evangelista L, Filippi L, Schillaci O. What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature. Ann Nucl Med. 2023;37:442\u201350. https:\/\/doi.org\/10.1007\/s12149-023-01852-x.","journal-title":"Ann Nucl Med"},{"key":"858_CR41","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/neuonc\/noaa023","volume":"22","author":"B Zinnhardt","year":"2020","unstructured":"Zinnhardt B, M\u00fcther M, Roll W, Backhaus P, Jeibmann A, Foray C, et al. TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. Neuro Oncol. 2020;22:1030\u201343. https:\/\/doi.org\/10.1093\/neuonc\/noaa023.","journal-title":"Neuro Oncol"},{"key":"858_CR42","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.37349\/etat.2024.00280","volume":"5","author":"BJ Hebert","year":"2024","unstructured":"Hebert BJ, Bradley J. The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer. Explor Target Anti-tumor Therapy. 2024;5:1365\u201372. https:\/\/doi.org\/10.37349\/etat.2024.00280.","journal-title":"Explor Target Anti-tumor Therapy"},{"key":"858_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010235","volume":"26","author":"R Noji","year":"2024","unstructured":"Noji R, Tohyama K, Nakamura S, Naito T, Oikawa Y, Kuroshima T, et al. Dynamic changes in circulating tumor DNA during immunotherapy for head and neck cancer: SHIZUKU-HN study. Int J Mol Sci. 2024;26:235. https:\/\/doi.org\/10.3390\/ijms26010235.","journal-title":"Int J Mol Sci"},{"key":"858_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1586\/17434440.3.6.699","volume":"3","author":"L Filippi","year":"2006","unstructured":"Filippi L, Schillaci O. SPECT\/CT with a hybrid camera: a new imaging modality for the functional anatomical mapping of infections. Expert Rev Med Devices. 2006;3:699\u2013703. https:\/\/doi.org\/10.1586\/17434440.3.6.699.","journal-title":"Expert Rev Med Devices"},{"key":"858_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/cbr.2006.21.41","volume":"21","author":"L Filippi","year":"2006","unstructured":"Filippi L, Schillaci O, Santoni R, Manni C, Danieli R, Simonetti G. Usefulness of SPECT\/CT with a hybrid camera for the functional anatomical mapping of primary brain tumors by [Tc99m] Tetrofosmin. Cancer Biother Radiopharm. 2006;21:41\u20138. https:\/\/doi.org\/10.1089\/cbr.2006.21.41.","journal-title":"Cancer Biother Radiopharm"},{"key":"858_CR46","first-page":"557","volume":"27","author":"O Schillaci","year":"2007","unstructured":"Schillaci O, Danieli R, Filippi L, Romano P, Cossu E, Manni C, et al. Scintimammography with a hybrid SPECT\/CT imaging system. Anticancer Res. 2007;27:557\u201362.","journal-title":"Anticancer Res"},{"key":"858_CR47","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2967\/jnumed.119.236943","volume":"61","author":"T Van den Wyngaert","year":"2020","unstructured":"Van den Wyngaert T, Elvas F, De Schepper S, Kennedy JA, Israel O. SPECT\/CT: Standing on the shoulders of giants, it is time to reach for the sky! J Nucl Med. 2020;61:1284\u201391. https:\/\/doi.org\/10.2967\/jnumed.119.236943.","journal-title":"J Nucl Med"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00858-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00858-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00858-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:40:14Z","timestamp":1782859214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00858-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["858"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00858-1","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization and writing the first draft: L.F., G.P., E.Ar., E.Ag., and L.E.; editing and revision: L.F. and L.E. All the authors read and approved the final version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors have any conflicts of interest that are directly relevant to the content of this article\n                      .\n                      Esra Arslan is an Editorial Board member of Molecular Diagnosis & Therapy. Esra Arslan was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (Participation and Publication)"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}